All News
Can Rheumatologists Accurately Diagnose axSpA in Patients with Chronic Back Pain?
Chronic low back pain is a common complaint that brings patients to the doctor’s attention. Although the majority of low back pain is mechanical in nature, an important minority is inflammatory in nature.
Read Article
Rheumatology Roundup - ACR 2023
Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
Read Article
#ACRbest Abstracts – Day 4
While there wasn’t much original new programming and research presented on the final day, that didn’t slow the RheumNow faculty from tweeting the noteworthy “Best of ACR” abstracts. Enjoy these below.
Read Article
The impact of SGLT2-inhibitor on SLE outcomes
Since chronic kidney disease is one of the strongest CV risk factors, any new strategy to reduce proteinuria and avoid a decline in renal function may likely improve patient outcomes. In large cardiovascular outcome trials, the use of a fairly new-kid-on-the-block therapy, sodium–glucose cotransporter-2 inhibitors (SGLT2i) appear to be both cardio and renal-protective. Would the use of SGLT2i have the same impact in SLE?
Read Article
Will CAR T Cells also treat RA?
Dr. Jonathan Kay reports on abstract 0424 from #ACR23.
https://t.co/shb8tpDut4 https://t.co/xLn36Yg9fn
Dr. John Cush RheumNow ( View Tweet)
RHEUM Survey Question: Your choice of a biologic in patients with SpA is mostly influenced by? Click here to answer: https://t.co/zevKhcDPjz
Dr. John Cush RheumNow ( View Tweet)
Watch: Ultrasound for PsA Stratification: Are We There Yet?
Dr. Aurelie Najm reports live from #ACR23
https://t.co/TeeBHl2LlU https://t.co/ObFtaJsTWp
Dr. John Cush RheumNow ( View Tweet)
New Biomarkers and Therapeutics Show Potential in Still's Disease
AOSD is a rare complex, sporadic, systemic autoinflammatory disease similar to sJIA characterized by sustained fever, salmon-colored rash, and arthritis
https://t.co/cGBBHsBdK7 https://t.co/a0EwBiTJSu
Dr. John Cush RheumNow ( View Tweet)
Urinary biomarkers precede loss of kidney function for lupus nephritis
In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.
https://t.co/MJb9F3uEgr https://t.co/oXvNLelE89
Dr. John Cush RheumNow ( View Tweet)
Less (Glucocorticoids) is More in Lupus Nephritis
Dr. Yuz Yusof talks with Dr. Amir Saxena about abstract 0781 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/EriaJvBPj9 https://t.co/x5hNIAgBz2
Dr. John Cush RheumNow ( View Tweet)
Difficult toTreat PsA: Mainly Difficult to Define!
Dr. Aurelie Najm reports on abstract 0777 from the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/vXDY47xWfS https://t.co/l5hJFc7blH
Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis Topic Panel
https://t.co/I3puVr5HWa https://t.co/sCzjnnDG1G
Dr. John Cush RheumNow ( View Tweet)
Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology
The top ACR2023 Plenary abstracts Dr. Dao ( @kdao2011) found impactful for her practice were...
https://t.co/aXut7l7b79 https://t.co/ATO5r5OzGK
Dr. John Cush RheumNow ( View Tweet)
ACR23 – Day 3 Report
F2F learning amidst miles of research and many young talented aside wizened establish presenters is such a welcome return to ACR, the way it should be.
https://t.co/TwmwfEQZdp https://t.co/Yo27c7ig8N
Dr. John Cush RheumNow ( View Tweet)
Watch: Lupus Nephritis Therapy Paradigm Shift
Dr. Yuz Yusof reporting on abstract 0782 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/poIVX74EnO https://t.co/tWlRlwTfH0
Dr. John Cush RheumNow ( View Tweet)
IV Secukinumab for AxSpa
The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis.
https://t.co/eDAWevPLkE https://t.co/AlWYGAQP5T
Dr. John Cush RheumNow ( View Tweet)
Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA
Dr. Robert Chao (Tysons, VA) discusses Abstract 0522 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/UmcbplfGhB https://t.co/R5Lr6Q0qHI
Dr. John Cush RheumNow ( View Tweet)
How early is early in psoriatic arthritis?
Is there a window of opportunity for treatment in PsA to ensure optimal outcomes?
https://t.co/SHA8Gdm1GD https://t.co/GbFfeB2Euw
Dr. John Cush RheumNow ( View Tweet)
Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions
https://t.co/MzksmSEUjf https://t.co/dxCIHxL1gc
Dr. John Cush RheumNow ( View Tweet)
Watch: SpA Insights: New Therapies
https://t.co/01wwJIkmRJ https://t.co/tMJufATzyd
Dr. John Cush RheumNow ( View Tweet)